IL155483A0 - Cyanoguanidine prodrugs - Google Patents

Cyanoguanidine prodrugs

Info

Publication number
IL155483A0
IL155483A0 IL15548301A IL15548301A IL155483A0 IL 155483 A0 IL155483 A0 IL 155483A0 IL 15548301 A IL15548301 A IL 15548301A IL 15548301 A IL15548301 A IL 15548301A IL 155483 A0 IL155483 A0 IL 155483A0
Authority
IL
Israel
Prior art keywords
cyanoguanidine
prodrugs
cyanoguanidine prodrugs
Prior art date
Application number
IL15548301A
Other languages
English (en)
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As filed Critical Leo Pharma As
Publication of IL155483A0 publication Critical patent/IL155483A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46Oxygen atoms
    • C07D213/50Ketonic radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
IL15548301A 2000-11-21 2001-11-14 Cyanoguanidine prodrugs IL155483A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25207800P 2000-11-21 2000-11-21
PCT/DK2001/000750 WO2002042265A2 (en) 2000-11-21 2001-11-14 Cyanoguanidine prodrugs

Publications (1)

Publication Number Publication Date
IL155483A0 true IL155483A0 (en) 2003-11-23

Family

ID=22954502

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15548301A IL155483A0 (en) 2000-11-21 2001-11-14 Cyanoguanidine prodrugs
IL155483A IL155483A (en) 2000-11-21 2003-04-15 Prodrugs of cyanoguanidine pyridinium and dihydropyridinylidene derivatives and pharmaceutical compositions comprising them

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL155483A IL155483A (en) 2000-11-21 2003-04-15 Prodrugs of cyanoguanidine pyridinium and dihydropyridinylidene derivatives and pharmaceutical compositions comprising them

Country Status (17)

Country Link
US (1) US6525077B2 (xx)
EP (2) EP2894149B1 (xx)
JP (1) JP4521157B2 (xx)
KR (1) KR100871577B1 (xx)
CN (1) CN100368401C (xx)
AU (3) AU1494702A (xx)
BR (1) BR0115514A (xx)
CA (1) CA2426601C (xx)
CZ (1) CZ305764B6 (xx)
ES (2) ES2643083T3 (xx)
HK (2) HK1073297A1 (xx)
HU (1) HU230544B1 (xx)
IL (2) IL155483A0 (xx)
MX (1) MXPA03004394A (xx)
PL (1) PL224371B1 (xx)
RU (1) RU2312858C2 (xx)
WO (2) WO2002042265A2 (xx)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711123D0 (en) * 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
US20030045515A1 (en) * 2001-05-24 2003-03-06 Lise Binderup Combination medicament for treatment of neoplastic diseases
CN1662502A (zh) * 2002-05-17 2005-08-31 利奥制药有限公司 氰基胍前药
ES2290454T3 (es) * 2002-05-17 2008-02-16 Leo Pharma A/S Profarmacos de cianoguanidina.
US7253193B2 (en) 2002-05-17 2007-08-07 Leo Pharma A/S Cyanoguanidine prodrugs
US20050101576A1 (en) * 2003-11-06 2005-05-12 Novacea, Inc. Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
JP2006523237A (ja) * 2003-04-03 2006-10-12 セマフォア ファーマシューティカルズ, インコーポレイテッド Pi−3キナーゼインヒビタープロドラッグ
EP1838696B1 (en) 2004-12-22 2016-03-09 Leo Pharma A/S Novel cyanoguanidine compounds
WO2007022964A2 (de) 2005-08-24 2007-03-01 Abbott Gmbh & Co. Kg Hetaryl substituierte guanidinverbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
US8173677B2 (en) * 2007-09-26 2012-05-08 Gemin X Pharmaceuticals Canada Inc. Compositions and methods for effecting NAD+ levels using a nicotinamide phosphoribosyl transferase inhibitor
WO2009072004A2 (en) * 2007-09-26 2009-06-11 Gemin X Pharmaceuticals Canada, Inc. Compositions and methods for effecting nad+ levels using a nicotinamide phosphoribosyl transferase inhibitor
US8101606B2 (en) 2007-11-12 2012-01-24 Washington University Neurofibromin pathway modulators
JP5688367B2 (ja) 2008-08-29 2015-03-25 トポターゲット・アクティーゼルスカブTopoTarget A/S 新規なウレアおよびチオウレア誘導体
WO2010088842A1 (zh) 2009-02-06 2010-08-12 天津和美生物技术有限公司 含有吡啶基氰基胍的药物组合物及其制备和应用
US20120270900A1 (en) 2009-07-17 2012-10-25 Topo Target A/S Novel method of treatment
US9224007B2 (en) * 2009-09-15 2015-12-29 International Business Machines Corporation Search engine with privacy protection
US9600134B2 (en) 2009-12-29 2017-03-21 International Business Machines Corporation Selecting portions of computer-accessible documents for post-selection processing
US8912184B1 (en) 2010-03-01 2014-12-16 Alzheimer's Institute Of America, Inc. Therapeutic and diagnostic methods
WO2011121055A1 (en) 2010-03-31 2011-10-06 Topotarget A/S Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety
US9676721B2 (en) 2010-09-03 2017-06-13 Forma Tm, Llc Compounds and compositions for the inhibition of NAMPT
CN103607888A (zh) * 2011-04-08 2014-02-26 斯法尔制药私人有限公司 取代的甲基甲酰基试剂以及使用所述试剂改进化合物的物理化学性质和/或药代动力学性质的方法
US9195853B2 (en) 2012-01-15 2015-11-24 International Business Machines Corporation Automated document redaction
JP2015521603A (ja) * 2012-06-15 2015-07-30 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアThe Regents Of The University Of California 脳癌の新規治療薬
CN104768931A (zh) * 2012-06-27 2015-07-08 向日葵研究有限责任公司(美国) 化合物及其治疗用途
AU2013326850B2 (en) 2012-10-04 2017-09-21 Inhibikase Therapeutics, Inc. Novel compounds, their preparation and their uses
US9892278B2 (en) 2012-11-14 2018-02-13 International Business Machines Corporation Focused personal identifying information redaction
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
CA2977521C (en) 2015-02-27 2024-03-19 Curtana Pharmaceuticals, Inc. 1-(aryl)-3-(heteroaryl) urea compounds and their use as olig2 inhibitors
WO2017162536A1 (en) 2016-03-21 2017-09-28 H. Lundbeck A/S Vortioxetine prodrugs
US20200138964A1 (en) * 2017-04-25 2020-05-07 Seikagaku Corporation Tertiary amine compound or imine compound-polymer conjugate and production method therefor
EP3590927A1 (en) * 2018-07-05 2020-01-08 Bayer Animal Health GmbH Novel compounds for controlling arthropods
US11174229B2 (en) 2018-10-29 2021-11-16 Kempharm, Inc. D-amphetamine compounds, compositions, and processes for making and using the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05501103A (ja) * 1989-06-26 1993-03-04 ザ・リサーチ・ファウンデーション・オヴ・ステイト・ユニヴァーシティ・オヴ・ニューヨーク ビス―アシルオキシメチル誘導体
GB9219472D0 (en) 1992-09-15 1992-10-28 Leo Pharm Prod Ltd Chemical compounds
GB9607219D0 (en) * 1996-04-04 1996-06-12 Smithkline Beecham Plc Novel compounds
GB9711125D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711124D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711119D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
GB9711123D0 (en) 1997-05-29 1997-07-23 Leo Pharm Prod Ltd Novel cyanoguanidines
AU4076500A (en) * 1999-04-09 2000-11-14 Shionogi Bioresearch Corp. (n)-substituted cyanoguanidine compounds
WO2000061561A1 (en) 1999-04-09 2000-10-19 Shionogi Bioresearch Corp. Cyanoguanidine compounds

Also Published As

Publication number Publication date
HK1073297A1 (en) 2005-09-30
ES2549260T3 (es) 2015-10-26
CN1589262A (zh) 2005-03-02
CZ20031303A3 (en) 2004-04-14
JP4521157B2 (ja) 2010-08-11
RU2312858C2 (ru) 2007-12-20
HU230544B1 (hu) 2016-11-28
ES2643083T3 (es) 2017-11-21
EP2894149A1 (en) 2015-07-15
WO2002042276A1 (en) 2002-05-30
HUP0400564A2 (hu) 2004-06-28
KR20030051861A (ko) 2003-06-25
CZ305764B6 (cs) 2016-03-09
HUP0400564A3 (en) 2008-03-28
JP2004520282A (ja) 2004-07-08
EP1339686B1 (en) 2015-09-16
AU1494702A (en) 2002-06-03
AU2002223511A1 (en) 2002-06-03
EP1339686A2 (en) 2003-09-03
BR0115514A (pt) 2003-12-30
CA2426601A1 (en) 2002-05-30
AU2002214947B2 (en) 2007-02-15
PL362864A1 (en) 2004-11-02
KR100871577B1 (ko) 2008-12-02
IL155483A (en) 2010-12-30
WO2002042265A3 (en) 2002-08-15
HK1212678A1 (zh) 2016-06-17
US6525077B2 (en) 2003-02-25
CA2426601C (en) 2015-01-13
MXPA03004394A (es) 2004-04-20
PL224371B1 (pl) 2016-12-30
EP2894149B1 (en) 2017-08-02
CN100368401C (zh) 2008-02-13
WO2002042265A2 (en) 2002-05-30
US20020165201A1 (en) 2002-11-07

Similar Documents

Publication Publication Date Title
HK1212678A1 (zh) 雙氰胺前體藥物
IL151073A0 (en) Antiviral prodrugs
AU3391801A (en) Pyridinylimidazoles
DZ3293A1 (fr) Arylpyrazines substitues
AU6227101A (en) Substituted iminoazines
IL151010A0 (en) Linezolid-crystal form ii
AU6803901A (en) Bis-arylsulfones
AU5825501A (en) Substituted benzoylcyclohexenones
PL358119A1 (en) Substituted phenyluracils
PL372761A1 (en) Cyanoguanidine prodrugs
AU6619001A (en) Liquid-pourers
EP1343494A4 (en) PROMOTERS TETRAPARTATES
AU4686401A (en) Hypotensors
AU8756801A (en) Thienopyrrolidinones
AU2360402A (en) Substituted phenyluracils
GB0111284D0 (en) Grating
SI1261613T1 (en) Gastro-specific prodrugs
AU1702P (en) Trailblazer Xanthostemon chrysanthus
AU2117P (en) Gauka Gaura lindheimeri
AU1852P (en) Tickit xTriticosecale
GB0027368D0 (en) Order form
GB0015191D0 (en) Advance arrangement
GB0015193D0 (en) Advance arrangement
GB0130486D0 (en) Windbeater one
GB0021697D0 (en) Pinger